Pfizer's Fragmin OK'd for pediatric symptomatic VTE

05:47 EDT 17 May 2019 | SmartBrief

Pfizer's Fragmin, or dalteparin sodium, was approved by the FDA to lessen the recurrence of symptomatic venous thromboembolis -More

Original Article: Pfizer's Fragmin OK'd for pediatric symptomatic VTE


More From BioPortfolio on "Pfizer's Fragmin OK'd for pediatric symptomatic VTE"

Quick Search


Relevant Topics

Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...